Jens M. Z.
- Country
- Germany
- Department
- Practice for Gastroenterology
Research Overview
- Top‑down mirikizumab versus azathioprine standard of care in newly diagnosed moderate‑to‑severe Crohn’s disease: 52‑week randomised open‑label trial
- Comparative Efficacy of Mirikizumab Versus Azathioprine and Glucocorticoids in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: A 52-Week Randomized Trial
Data & Insights
Has run more than one trial at 6 of 21 partner sites.
Specializations
Inflammatory Bowel Disease
Focus on ulcerative colitis as a primary condition within IBD.
- Disease pathophysiology
- Risk stratification
- Long‑term disease monitoring
Clinical expertise is anchored in gastroenterology practice in Hanover, Germany.
Therapeutic Strategies
Development and evaluation of treatment regimens for ulcerative colitis, including induction and maintenance approaches.
- Top‑down therapy with mirikizumab
- Standard of care with azathioprine
- Oral controlled‑ileocolonic‑release nicotinamide
Emphasis on comparative effectiveness and early disease control.
Biologic and Small Molecule Therapies
Investigation of targeted biologics and oral agents for modulating immune response in ulcerative colitis.
- Anti‑IL‑23 monoclonal antibodies
- Nicotinamide pathways
- Combination with glucocorticoids
Aims to expand therapeutic options beyond conventional immunosuppression.
Clinical Outcomes and Endoscopic Assessment
Assessment of endoscopic response, histologic improvement, and symptomatic remission as endpoints.
- Mucosal healing metrics
- Patient‑reported outcome measures
- Long‑term remission sustainability
Outcomes inform treatment algorithms for moderate to severe disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.